Novo Nordisk ramping up insulin production with 450-job project

If you listen to drugmakers talk, the world diabetes market is fraught with peril. Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition, while Sanofi ($SNY) says its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo, which kicked off one piece of a huge production buildup on Wednesday. All told, the expansion will add more than 1,200 jobs to the drugmaker. More from FiercePharma

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.